Drug development company BiolineRX announced that it has received approval from Israel’s Ministry of Health to commence a Phase II trial of its treatment for inflammatory bowel disease (IBD). The company reported that the Phase II trial will be an open-label study to evaluate the efficacy, safety and tolerability of the treatment, BL-7040, in up to 20 patients. The results are expected by the end of 2012. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments